Business Context and Reporting Period
This Form 8-K was filed by ImmunityBio, Inc. on March 23, 2022. The report discloses the establishment of the 2022 Long-Term Incentive Program (LTIP) and the subsequent grant of stock option awards to named executive officers (NEOs) under the Company's Amended and Restated 2015 Equity Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
On March 23, 2022, the Compensation Committee granted option awards to three NEOs. The exercise price for all awards was set at $5.83, equal to the closing stock price on the grant date. The awards vest annually in equal one-third installments beginning on the first anniversary of the grant date, contingent on continued service. Additionally, half of the shares underlying each award are subject to the achievement of a financial goal.
| Executive Name | Number of Shares | Exercise Price |
|---|---|---|
| Dr. Patrick Soon-Shiong | 700,000 | $5.83 |
| Richard Adcock | 700,000 | $5.83 |
| David Sachs | 250,000 | $5.83 |
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard vesting conditions tied to service and financial goals. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the specific financial goals required to vest the performance-based portion of the option awards.
- Confirm the total number of shares available under the 2015 Equity Incentive Plan post-grant.
- Review the Company's most recent 10-K or 10-Q for current liquidity and cash burn rates, as this 8-K does not provide financial statements.